The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice

Alexander Weidemann, …, David Kleinfeld, Randall S. Johnson


A key adaptation to environmental hypoxia is an increase in erythropoiesis, driven by the hormone erythropoietin (EPO) through what is traditionally thought to be primarily a renal response. However, both neurons and astrocytes (the largest subpopulation of glial cells in the CNS) also express EPO following ischemic injury, and this response is known to ameliorate damage to the brain. To investigate the role of glial cells as a component of the systemic response to hypoxia, we created astrocyte-specific deletions of the murine genes encoding the hypoxia-inducible transcription factors HIF-1α and HIF-2α and their negative regulator von Hippel–Lindau (VHL) as well as astrocyte-specific deletion of the HIF target gene Vegf. We found that loss of the hypoxic response in astrocytes does not cause anemia in mice but is necessary for approximately 50% of the acute erythropoietic response to hypoxic stress. In accord with this, erythroid progenitor cells and reticulocytes were substantially reduced in number in mice lacking HIF function in astrocytes following hypoxic stress. Thus, we have demonstrated that the glial component of the CNS is an essential component of hypoxia-induced erythropoiesis.

Find the latest version:

http://jci.me/39378-pdf
The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice

Alexander Weidemann,1 Yann M. Kerdiles,1 Karl X. Knaup,2 Christopher A. Rafie,3 Adam T. Boutin,1 Christian Stockmann,1 Norihiko Takeda,1 Miriam Scadeng,4 Andy Y. Shih,3 Volker H. Haase,5 M. Celeste Simon,6 David Kleinfeld,3 and Randall S. Johnson1

1Division of Biology, University of California, San Diego, La Jolla, California, USA. 2Nikolaus-Fiebinger-Center for Molecular Medicine, Erlangen, Germany. 3Department of Physics and 4Center for Functional MRI, University of California, San Diego, La Jolla, California, USA. 5Vanderbilt University Medical Center, Nashville, Tennessee, USA. 6Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA.

A key adaptation to environmental hypoxia is an increase in erythropoiesis, driven by the hormone erythropoietin (EPO) through what is traditionally thought to be primarily a renal response. However, both neurons and astrocytes (the largest subpopulation of glial cells in the CNS) also express EPO following ischemic injury, and this response is known to ameliorate damage to the brain. To investigate the role of glial cells as a component of the systemic response to hypoxia, we created astrocyte-specific deletions of the murine genes encoding the hypoxia-inducible transcription factors HIF-1α and HIF-2α and their negative regulator von Hippel–Lindau (VHL) as well as astrocyte-specific deletion of the HIF target gene Vegf. We found that loss of the hypoxic response in astrocytes does not cause anemia in mice but is necessary for approximately 50% of the acute erythropoietic response to hypoxic stress. In accord with this, erythroid progenitor cells and reticulocytes were substantially reduced in number in mice lacking HIF function in astrocytes following hypoxic stress. Thus, we have demonstrated that the glial component of the CNS is an essential component of hypoxia-induced erythropoiesis.

Introduction

The erythropoietin (EPO) hormone is the chief regulator of red blood cell production in mammals, and its rate of synthesis is highly responsive to changes in physiologic oxygenation (1). Studies of this relationship between oxygen and red blood cell production date back to Vauldt’s work at the end of the nineteenth century (2). Dissection of the mechanisms for induction of the Epo gene by low-oxygen conditions led to the discovery of a hypoxia responsive element (HRE) in the 3’ enhancer region of the gene; a binding site within the Epo gene was found for a family of transcription factors, which were subsequently termed hypoxia-inducible factors (HIFs) (3).

HIF is a heterodimeric DNA-binding complex composed of 2 basic helix-loop-helix proteins of the PAS family: the constitutive non-oxygen-responsive subunit HIF-1α (also termed ARNT) and 1 of either hypoxia-inducible α-subunits, HIF-1α or HIF-2α (reviewed in refs. 4, 5). HIF-α subunits are rapidly degraded in normoxia but highly inducible by hypoxia. The interface between oxygen and the HIF-α subunits in normoxia is in part the hydroxylation of 2 prolyl residues in the oxygen-dependent degradation domain of the α subunits. HIF-α hydroxylation under normoxia regulates the interaction with the von Hippel–Lindau tumor suppressor protein (pVHL), which targets HIF-α for proteolysis by the ubiquitin-proteasome pathway (6).

EPO synthesis is only detectable in a small number of tissues, including the kidney, liver, and the CNS (reviewed in refs. 7, 8). The kidney produces a large fraction of the circulating EPO in adult mammals (9), and it is clear that nonrenal EPO does not compensate for the loss of renal EPO production in patients with chronic kidney disease. Thus, these patients rely on exogenous recombinant EPO for treatment of anemia.

A “hemopoietin” produced in the CNS was proposed by Carnot in 1906 (10); and indeed, EPO mRNA can be detected in the CNS (11). However, the physiology of cerebral EPO is incompletely understood, although some studies have shown it to play roles in neural development and neuroprotection (reviewed in ref. 12). Controversy exists, for example, as to whether EPO can cross the blood-brain barrier (BBB) (12, 13). This has led to a proposed paracrine rather than an endocrine role for the hormone in the CNS response to hypoxia (14).

In the CNS, both neurons (15) and astrocytes (16, 17) are capable of EPO synthesis. Astrocytes make up the largest subpopulation of glial cells in the CNS and are a key factor in alleviating ischemic damage to neurons (18, 19). We therefore generated conditional deletions in astrocytes of the major factors that mediate hypoxic transcriptional response and regulate EPO, i.e., HIF-1α, HIF-2α, and VHL as well as the HIF target gene, which encodes the VEGF. Here, we show through loss-of-function mutations that the CNS is an essential part of a systemic erythropoietic response to hypoxia and demonstrate that the CNS directly participates in hypoxia-induced erythropoiesis.

Results

Recombination in murine, GFAP-expressing astrocytes. Mice that express Cre recombinase under an astrocyte-specific promoter (2) (glial fibrillary acidic protein [GFAP] with an internal ribosomal entry site [IRES] element for cotranslation of Cre and LacZ proteins [GFAPCre-IRES-LacZ]) were crossed with mice homozygous for conditional, loxP-flanked alleles of HIF-1α (21), HIF-2α (22), and VHL (23) (resulting in, e.g., GFAPCre+/VHL+/+ mice). PCR ampli-

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 119:3373–3383 (2009). doi:10.1172/JCI39378.
Figure 1
Generation of mice deficient for the genes encoding HIF-1α, HIF-2α, and VHL in astrocytes. (A) Genomic PCR analysis of DNA isolated from brain (B), liver (L), and kidney (K) with primers amplifying the conditional (2-lox), the recombined (1-lox) and the WT allele. Recombination of the conditional allele was detected in brain, but not in liver or kidney, in GFAPCre+/HIF-1α^+/f^f, GFAPCre+/HIF-2α^+/f^f, and GFAPCre+/VHL^+/f^f mice, respectively (representative photograph). (B) Cre protein colocalizes with the astrocyte marker GFAP in the hippocampus of adult GFAPCre-positive animals (representative photographs). Scale bars: 100 μm. (C) Cre protein is expressed in brains of GFAPCre-positive animals, but not in liver and kidney (representative photographs). Scale bars: 100 μm. (D) Both HIF-1α and HIF-2α protein are not detectable in brain sections of GFAPCre-negative animals in normoxia. In contrast, both isoforms are strongly induced in brains of normoxic GFAPCre+/VHL^+/f^f mice (representative photographs). Scale bars: 100 μm. (E) HIF-α isoforms are not stabilized in livers and kidneys of GFAPCre+/VHL^+/f^f animals. WT animals treated with 0.1% carbon monoxide (CO) are shown as positive controls (representative photographs). Scale bars: 100 μm. (F) Immunoblots show the normoxic induction of both HIF-α isoforms in whole-brain lysates, but not in liver or kidney of GFAPCre+/VHL^+/f^f mice. The respective isoform is specifically deleted in brains of GFAPCre+/VHL^+/f^f/HIF-1α^+/f^f and GFAPCre+/VHL^+/f^f/HIF-2α^+/f^f double-knockout animals.
fication of genomic DNA of brain, liver and kidney shows DNA is recombined, resulting in deletion in 3 loci (Hif1a, Epas1, and Vhl) in brain-derived DNA of GFAPCre+ animals but not in kidney- or liver-derived DNA (Figure 1A). Cre recombinase protein expression mimics astrocyte distribution (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI39378DS1) and colocalizes to GFAP (Figure 1B) but not to the neuronal marker NeuN (Supplemental Figure 1B). In contrast, nonastrocytic tissues do not express Cre recombinase in GFAPCre-positive animals (Figure 1B).

In addition, loss of the negative regulator of the HIF-α genes, VHL, resulted in detectable expression of both HIF-1α and HIF-2α protein in normoxic brains as determined immunohistologically (Figure 1D) and by immunoblot (Figure 1F). As expected, HIF-α isoforms are not stabilized in livers or kidneys of GFAPCre+/VHL−/− mice and are thus undetectable in tissue sections (Figure 1E) and in immunoblots of whole-organ lysates (Figure 1F). Under control conditions, neither HIF-α isofrom is detectable in substantial amounts in WT animals.

Severe pathology due to loss of VHL in astrocytes. Mice harboring conditional deletions of HIF-1α, HIF-2α, or VHL in astrocytes are all born at expected ratios and are viable at birth (data not shown). However, animals with deletion of VHL in astrocytes fail to thrive and are significantly smaller than GFAPCre-negative, HIF-1α, or HIF-2α conditional knockout animals at the age of 6 weeks (GFAPCre-negative: 21.16 ± 0.7 g vs. GFAPCre+/VHL−/−: 17.13 ± 0.9 g; Figure 2). Knockout of VHL in astrocytes reduces survival, induces hydrocephalus, and leads to severe erythrocytosis in mice. (A) The weight of 6-week-old GFAPCre+/VHL−/− animals (n = 8) is significantly less than that of control (GFAPCre−; n = 23), GFAPCre+/HIF-1α−/− (n = 9), and GFAPCre+/HIF-2α−/− (n = 8) animals. Data represent medium and interquartile ranges. (B) Survival is significantly reduced to 18.4 weeks in GFAPCre+/VHL−/− (n = 45) compared with control animals (GFAPCre−; n = 46). It is normal in GFAPCre+/HIF-1α−/− (n = 25) and in GFAPCre+/HIF-2α−/− mice (n = 57). Data represent median survival (weeks). (C) GFAPCre+/VHL−/− mice (lower panel) develop severe hydrocephaly (representative T2 weighted MRI photographs; cerebrospinal fluid appears white). (D) Hematocrits at the age of 10 weeks are not different in control (GFAPCre−; n = 19), GFAPCre+/HIF-1α−/− (n = 10), and GFAPCre+/HIF-2α−/− animals (n = 8). In contrast, GFAPCre+/VHL−/− mice (n = 7) exhibit a striking elevation of the hematocrit. (E) Plasma EPO levels in GFAPCre+/VHL−/− animals (n = 12) are significantly increased compared with those in control mice (GFAPCre−; n = 34). No difference from WT plasma EPO levels is detected in GFAPCre+/HIF-1α−/− (n = 10) and GFAPCre+/HIF-2α−/− mice (n = 6). Data represent mean ± SEM. (F) Red blood cell count (upper panel) and hemoglobin concentration (lower panel) are both significantly higher in GFAPCre+/VHL−/− mice (n = 6) than in control animals (GFAPCre−; n = 5), which indicates pathological erythrocytosis. Data represent mean ± SEM.
Figure 2A and Supplemental Figure 1C). Both HIF-1α and HIF-2α conditional knockout animals have a normal life span and normal fertility and show no obvious neurologic defects (Figure 2B and data not shown). In GFAPCre+/VHL−/− animals, however, survival is significantly reduced relative to WT controls (Figure 2B). They exhibit severe locomotive defects, a dome-shaped skull (Supplemental Figure 1C), increased permeability of the BBB (Supplemental Figure 1D), and hydrocephalus, as assessed by functional MRI (fMRI) (Figure 2C). No signs of increased ventricular space were found in fMRI analyses of GFAPCre+/HIF-1α−/− and GFAPCre+/HIF-2α−/− mice (data not shown).

Surprisingly, it was found that the hematocrit is dramatically elevated (to 79.6% ± 0.8% in 10-week-old GFAPCre+/VHL−/− mice) when VHL mutants are compared with control animals (48.5% ± 0.8%; Figure 2D). In contrast, hematocits of GFAPCre+/HIF-1α−/− and GFAPCre+/HIF-2α−/− mice are not significantly different from those of WT mice.

The increased hematocrit found in VHL conditionally null mice is driven by elevated EPO plasma levels: deletion of VHL in astrocytes increases the plasma EPO levels from 213.3 ± 27.9 pg/ml in WT controls to 1106 ± 72.4 pg/ml in GFAPCre+/VHL−/− mice (Figure 2E). Reticulocyte numbers are significantly increased in GFAPCre+/VHL−/− animals (data not shown), as are the red blood cell numbers (8.078 ± 0.8 × 10¹¹/mm³ vs. 13.33 ± 0.4 × 10¹¹/mm³) and hemoglobin concentrations (14.32 ± 0.6 g/dl vs. 23.63 ± 1.3 g/dl; Figure 2F).

Taken together, these data show that deletion of VHL in astrocytes induces a severe pathology, with reduced survival, hydrocephaly, and excessive erythrocytosis. None of these phenotypes were detected in mice lacking HIF-1α or HIF-2α in astrocytes.

Excessive erythrocytosis after loss of VHL is dependent on HIF-2α overexpression in astrocytes. A number of studies have shown that in the context of loss of VHL function, HIF-2α becomes the dominant HIF-α isoform (24–27). To investigate which HIF-α isoform is the major determinant of phenotypic changes in the tissue-specific deletion of VHL in astrocytes, deletions of VHL and HIF-1α (GFAPCre+/VHL−/−/HIF-1α−/−) and VHL and HIF-2α (GFAPCre+/VHL−/−/HIF-2α−/−) in astrocytes were generated. These double mutants are viable, but removal of VHL and HIF-1α in astrocytes does not improve survival rate relative to VHL deletion alone and in fact significantly shortens it, to 16.1 weeks (Figure 3A). In contrast, loss of VHL and HIF-2α gives rise to mice with a normal life span (Figure 3A), and these mice have growth curves indistinguishable from those of WT littermates (data not shown).

The hematocrit at the age of 12 weeks in GFAPCre+/VHL−/−/HIF-1α−/− animals was 81.7% ± 1%; this was significantly elevated in GFAPCre+/VHL−/−/HIF-1α−/−/HIF-1α−/− mutants (to 86.8% ± 0.8%; Figure 3B). In contrast, the hematocits of GFAPCre+/VHL−/−/HIF-2α−/− were not significantly different from those of control mice (48.8% ± 0.7%). Augmented erythropoiesis and erythrocytosis also had profound effects on other organs: the spleen (a site of extramedullary erythropoiesis in the mouse; ref. 28) and the heart of GFAPCre+/VHL−/− and GFAPCre+/VHL−/−/HIF-1α−/− animals were significantly enlarged compared with those organs in both WT control and GFAPCre+/VHL−/−/HIF-2α−/− animals (Supplemental Figure 1E). The presence of hydrocephaly, already detectable in 3-week-old mice, was also clearly HIF-2α dependent (Supplemental Figure 1F), further supporting the notion that HIF-2α is the critical determinant of the phenotype induced by deletion of VHL in astrocytes.

Blood analyses indicated that hematocrits began to rise after 3 weeks of age and reached peak levels at 5 weeks in GFAPCre+/VHL−/−/HIF-1α−/− animals and at 6 weeks in GFAPCre+/VHL−/− mice (Figure 3C). Plasma concentration of EPO in adult animals was not significantly different in GFAPCre+/VHL−/−/HIF-1α−/− and in GFAPCre+/VHL−/− animals (1154 ± 210.9 pg/ml vs. 1077 ± 94.6 pg/ml; Figure 3D), but plasma EPO in GFAPCre+/VHL−/−/HIF-2α−/− mice was reduced to the levels seen in WT control animals.

**Increased EPO expression in astrocytes causes suppression of renal but not hepatic EPO mRNA levels.** Deletion of VHL in astrocytes dramatically increased cerebral EPO mRNA levels relative to those found in control animals (1801 ± 208.3–fold; Figure 3E). This increase in EPO expression was almost eliminated with a concurrent deletion of HIF-2α, but not HIF-1α (Figure 3E). In animals lacking VHL or both VHL and HIF-1α in astrocytes, EPO mRNA expression in the kidney was suppressed to almost undetectable levels (Figure 3F). In contrast, EPO expression was not significantly different in kidneys of GFAPCre+/VHL−/−/HIF-2α−/− compared with control animals (1.393 ± 0.4–fold vs. 1.128 ± 0.1–fold). Intriguingly, hepatic EPO expression was not suppressed; while it was not significantly different from WT levels in GFAPCre+/VHL−/− and GFAPCre+/VHL−/−/HIF-2α−/− mice, it was somewhat elevated in GFAPCre+/VHL−/−/HIF-1α−/− animals (13.2 ± 5.5–fold; Figure 3G). This indicates that polycythemic feedback inhibition of EPO synthesis was not acting on the liver. Ectopic expression of HIF-1α and HIF-2α was not detectable in livers of GFAPCre+/VHL−/−/HIF-1α−/−/HIF-2α−/− mice (Figure 3H).

Deletion of astrocytic expression of VEGF can act to suppress nonhematologic phenotypes induced by loss of VHL. Deletion of VHL in astrocytes...
not only induced EPO, but also the HIF target gene VEGF, in a HIF-2α–dependent fashion (Supplemental Figure 2C); this was correlated with an expansion of vessels in the CNS (Supplemental Figure 2D). The vessels in the CNS of GFAPCre+/VHL+/−/VEGF+/−/HIF-1α−/−/− mice were more tortuous and had an increased diameter; the blood flow velocity through them was consequently reduced (Supplemental Figure 2, E and F). Mutants with deletions of VHL and VEGF (29) in astrocytes were generated to determine whether loss of VEGF suppressed the phenotypic effects of VHL deletion. The mean survival of GFAPCre+/VHL+/−/VHL+/−/HIF-1α−/−/− mice was prolonged to 22.6 weeks, but was still significantly shorter than that of WT animals (Supplemental Figure 3A). They exhibited a high hematocrit (Figure 4A), with elevated EPO mRNA in the brain (Figure 4B) and high plasma EPO concentrations (Figure 4C). MRI imaging showed that GFAPCre+/VHL+/−/VHL+/−/HIF-1α−/−/− mice did not develop hydrocephaly; however, the brains appeared smaller in size than those of GFAPCre-negative littermates (Supplemental Figure 3B). Thus, concomitant deletion of VEGF in the VHL-null background in astrocytes suppressed some of the phenotypic effects of VHL loss, although this did not affect the hematological changes observed in these animals.

Targeted deletion of HIF-2α in astrocytes reduces systemic erythropoietic response to acute hypoxia. The data described above indicate that deletion of VHL in astrocytes causes excessive systemic erythropoiesis, driven by HIF-2α–dependent EPO expression in the CNS. This suggests a potential role for astrocytes in erythropoiesis. However, secondary effects associated with the pathology of VHL deletion in the CNS might influence the erythropoietic phenotype observed. To investigate the systemic importance of astrocyte HIF function independently, we examined erythropoietic stress responses to hypoxia in GFAPCre+/HIF-1α−/−/−, GFAPCre+/HIF-2α−/−/−, and GFAPCre+/HIF-1α−/−/−/HIF-2α−/−/− mutant animals.

Exposure of WT mice to 7.5% oxygen for 10 hours induced EPO mRNA expression 16.75 ± 2.7–fold in the brain relative to levels seen at normoxia (1.63 ± 0.6–fold; Figure 5A). Deletion of HIF-1α in astrocytes did not significantly change the hypoxic EPO induction (to 18.17 ± 2.6–fold); however, we found that in GFAPCre+/HIF-2α−/−/− mice, the hypoxia-induced increase in EPO mRNA levels was significantly reduced, to 2.82 ± 0.3–fold, which indicates that the hypoxic induction is critically dependent on the presence of HIF-2α. It also demonstrates that the majority of EPO mRNA response in the CNS was due to HIF-2α–driven activation of EPO synthesis in astrocytes.

Deletion of both HIF-1α and HIF-2α together in astrocytes further reduced brain EPO mRNA levels significantly, both in normoxia (to 0.29 ± 0.03–fold) and in hypoxia (to 1.78 ± 0.2–fold; Figure 5A). This argues that HIF-1α does participate in regulation of EPO synthesis in this tissue when HIF-2α is absent.

Plasma EPO concentrations were also significantly reduced, by about 35%, in hypoxic GFAPCre+/HIF-2α−/−/− mice when compared with EPO detected in plasma of hypoxic WT control mice (733.6 ± 108 pg/ml vs. 1138 ± 121.5 pg/ml; Figure 5B). Animals with astrocytic deletions of both HIF-1α and HIF-2α had an even greater reduction in plasma EPO following hypoxia, with amounts that were approximately half those seen in hypoxic, WT controls (555.7 ± 81.2 pg/ml; Figure 5B).

These data, coupled to an absence of changes in renal or hepatic EPO response in these animals in hypoxia (Figure 5, C and D), indicate that no renal or hepatic compensation occurs in mutant animals and thus that the diminished EPO originating from HIF-α-null astrocytes is directly responsible for reducing systemic circulating EPO protein levels.

Loss of HIF-2α in astrocytes inhibits systemic response to acute blood loss. Bleeding represents another stress to the erythropoietic system that is compensated for by an acute induction of EPO expression, followed by a burst of erythropoiesis. To determine the role of CNS-induced response to blood loss, phlebotomy was performed to lower animal hematocrits by approximately 10%. Consistent with the effects seen after hypoxic exposure, the plasma EPO concentration 14 hours after bleeding was significantly reduced in GFAPCre+/HIF-2α−/−/− mice compared with WT littermates (833.0 ± 148.7 pg/ml vs. 1303 ± 124.1 pg/ml; Figure 6A); this difference disappears after 72 hours, indicating that after a diverse pathophysiological stimulus, astrocyte-derived EPO is necessary for an acute systemic response.

The principal biological function of EPO is the inhibition of apoptosis of erythroid progenitor cells, which in turn facilitates their proliferation and differentiation (1). To determine the functional role of astrocyte-derived EPO, proliferation of erythroid progenitor cells (detected by the cell-surface markers CD71 and
Ter119) induced by anemia in spleen and bone marrow was analyzed by flow cytometry in WT mice, GFAPCre-negative (GFAPCre−) mice, and mice with Cre expression in astrocytes and therefore lacking the conditional allele (i.e., GFAPCre+ HIF-2αCre−). The increase of CD71hi/Ter119pos erythroid progenitor cells was significantly reduced in the bone marrow (from 1.25 ± 0.04-fold to 1.08 ± 0.03-fold) and in the spleen (from 2.420 ± 0.24-fold to 1.778 ± 0.08-fold; Figure 6, B and C) of GFAPCre+ HIF-2αCre− mutant animals. Moreover, the reticulocyte number in the peripheral blood was also reduced significantly, by approximately one-third, in the GFAPCre+ HIF-2αCre− mice 72 hours after bleeding (5.58% ± 0.35% vs. 8.43% ± 0.89%; Figure 6D).

Taken together, these data demonstrate that in acute stress, astrocyte-derived EPO is a critical contributor to the systemic pool of circulating plasma EPO and that this contribution plays an essential role in stress-induced erythropoiesis.

**Discussion**

Historically, the systemic effects of EPO produced in the CNS have been thought to be negligible, except for rare cases of neurogenic polycythemia, which have generally been based on incidences of cerebellar hemangioblastomas (30–32). Interestingly, though, at least one case exists in the literature in which polycythemia coincided with an astrocyte-derived tumor (i.e., a glioblastoma) (33).
There have been a number of attempts to tie induction of erythropoiesis to the CNS. One series of experiments in the early 1960s induced erythropoiesis by “cerebral stimulation” in rabbits (34) and in cats and dogs (35); a significant fraction of the animals developed reticulocytosis in these experiments. Interestingly, a carefully investigated case report of actual erythrocytosis caused by a transient occlusion of the middle cerebral artery further supports a model for CNS-derived EPO acting systemically (36).

We describe here evidence that astrocyte-derived EPO contributes to a systemic erythropoietic response and that this occurs in a HIF-α–dependent fashion. We first show that deletion of the VHL gene in astrocytes leads to a HIF-2α–driven pathologic erythrocytosis, which is correlated with an endogenous overproduction of EPO in the CNS. We then demonstrate that loss of HIF-α response in astrocytes reduces systemic plasma EPO concentrations by as much as half, after both hypoxia and blood loss. And, correlated with lower circulating plasma EPO after blood loss, the increase of erythroid progenitors in both spleen and bone marrow is blunted after loss of HIF-2α in astrocytes.

Deletion of VHL in astrocytes induces a severe pathology with gross macroscopic defects such as hydrocephalus, an exaggerated EPO mRNA induction that drives polycythemia, and reduced survival. Interestingly, the nonhematological aspects of the phenotype precede the polycythemia, which indicates distinct pathoge-
netic entities. It has previously been shown in other mouse models that polycythemia typically develops after the first 4 to 5 weeks after birth (37, 38), potentially due to an inability of the immature bone marrow and spleen to fully respond to hyperstimulation by elevated EPO concentrations.

The premature death in mice with a conditional deletion of VHL in astrocytes is most likely a combination of the various factors investigated here. Although this extensive pathology does not recapitulate human VHL disease, it constitutes an important model for studying pathologic effects of HIF-α overexpression in the CNS. We show that in the CNS and in the absence of neoplasms, the phenotype generated by loss of VHL is mainly dependent on the bone marrow and spleen to fully respond to hyperstimulation by peripherally administered EPO and the CNS (13) that argue for a direct effect on those organs' EPO synthesis as an explanation for the observed levels.

In the CNS, EPO is produced in neurons and in astrocytes (15, 16). Current models argue that CNS-derived EPO is essential for neuronal development and localized protective effects (12). However, there are indications for crosstalk between peripherally administered EPO and the CNS (13) that argue for movement of EPO across the BBB (39). Our findings provide evidence that this movement is not only unidirectional, but also that efflux of CNS-derived EPO occurs. Indeed, in mice with conditional deletion of VHL in astrocytes, the elevation of EPO levels results in suppression of renal EPO expression, potentially by the elevated hematocrit (40, 41).

Although the data presented here indicate that astrocyte EPO is predominantly regulated by HIF-2α, HIF-1α can also contribute to induction of the response during hypoxia, at least in the absence of HIF-2α. This is somewhat surprising with respect to reports of in vitro data that demonstrate an exclusive HIF-2α regulation of EPO in astrocytes (18). However, in anemia, a minor role for HIF-1α in EPO regulation has been suggested (42), and this highlights the complexity of hypoxic EPO regulation. Additionally, our group has demonstrated a HIF-1α- and vascular flow-dependent change in EPO production stemming from epidermal deletion of HIF-1α (43). Although cerebral blood flow (CBF) could be a factor in some of the CNS-dependent changes in EPO seen here, the lack of change in renal or hepatic EPO mRNA levels would argue against a direct effect on those organs' EPO synthesis as an explanation for these observations.

It is intriguing, however, to speculate regarding whether acute changes in CBF might be involved in hypoxic response and EPO generation, since it is known that acute hypoxia and anemia increase CBF (44, 45). Furthermore, there remain mechanistic questions concerning how CNS-derived EPO acts in the systemic erythropoietic response. Our data suggest that the major EPO-producing organs act together to elevate plasma EPO concentration as quickly and effectively as possible. Differential kinetics of EPO mRNA expression in the CNS and kidney have been shown (46) and might explain why we observe reduced EPO concentrations in conditional HIF-2α-knockout animals as late as 12 hours after the induction of hypoxia or anemia. The lack of difference in EPO concentrations 72 hours after bleeding in both WT and GFAP-HIF-2αlox/lox mice thus argues for contribution of glial EPO primarily in an acute response. Given the intense utilization of oxygen by the brain, a tie to an acute erythropoietic response would fit with a role for a link between CNS EPO release and a functional demand for immediate increases in oxygen transport. The participation of the CNS in erythropoiesis would thus occur during acute states in which there is a need for maximal participation of all tissues for induction of EPO (an "all hands on deck" response). An important question to address in the future would be why increased renal or hepatic response cannot accomplish this; another is what advantage a third source of plasma EPO confers on the hypoxic organism.

In conclusion, we have shown here through gain-of-function and loss-of-function mutations in mice that approximately half of the systemic plasma EPO increase following acute hypoxic insult is dependent on a HIF-α-driven astrocytic response. Given that HIF mediates the increases in plasma EPO that we have described, these findings also demonstrate that compounds that activate HIF could potentially induce EPO expression in the brain, which in turn could act to increase erythropoiesis independently of renal function.

**Methods**

*Transgenic mice.* All procedures involving animals were approved by the UCSD Animal Care Committee, which serves to ensure that all US government guidelines concerning animal experimentation are met. Generation of mice carrying the flox-flanked conditional alleles of HIF-1α, HIF-2α, VEGF, and VHL was described previously (21–23, 29). Astrocyte-specific inactivation was achieved by cross-breeding those mice to GFAP-Cre transgenic mice (provided by D. Guttman, Washington University, St. Louis, Missouri, USA; ref. 20) in C57BL/6 background or the respective double knockouts (VHL/HIF-1α, VHL/HIF-2α, and VHL/VEGF) in mixed background. Cre-negative homozygous littermates for the conditional alleles were used as controls. Animals were between 10 and 14 weeks at the time of the experiments.

**Hypoxia exposure and bleeding anemia.** Animals were exposed to 7.5% oxygen for 10 hours in a hypoxic animal chamber (BioSpherix Ltd.) and sacrificed immediately thereafter. 180 μl blood was taken from anesthetized mice via retroorbital bleeding, and animals were sacrificed after either 14 hours, 48 hours, or 72 hours.

**Hematological analysis.** Hematocrit analysis was performed in heparinized blood tubes (Fisher Biosciences) after centrifugation according to the manufacturer's protocol. Other hematological parameters were analyzed in the UCSD Animal Care Program Diagnostic Laboratory. For reticulocyte count, blood smears of 1:1 diluted blood with new methylene blue were analyzed. To reduce counting errors, 10 random fields with over 100 blood cells each were counted per animal.

**DNA recombination analysis.** DNA from tissue was extracted with QIAGEN DNEasy kit according to the manufacturer's protocol. 25 ng of genomic DNA of brain, liver, and kidney was amplified by PCR with primers specific for WT and floxed alleles. Primer sequences are in Supplemental Methods. PCR products were visualized on 2.5% agarose gels containing 0.005% ethidium bromide (Sigma-Aldrich).

**RNA analysis by reverse transcription and real-time quantitative PCR.** Total RNA was isolated with TRIzol reagent (Invitrogen) from homogenized tissue. First-strand synthesis was performed with 1 μg of total RNA by the SuperScript System (Invitrogen) according to the manufacturer's protocol. For real-time PCR analyses, cDNAs were diluted to a final concentration of 5 ng/μl (for EPO) or 1 ng/μl (other HIF-target genes) and amplified in SYBR Green or TaqMan Universal Master Mix (Applied Biosystems) with an ABI PRISM 7700 sequence detection system (Applied Biosystems). Expression levels were related to 18S using the ΔCt method. Primer sequences are in Supplemental Methods.

**Immunohistochemistry.** Mice were transcardially perfused with PBS containing 0.5 mM EDTA followed by 4% PBS-buffered paraformaldehyde (Sigma-Aldrich), and tissue was embedded in paraffin. HIF immunohistochemistry was done as described before (47). For other stainings, 5 μm sections were subjected to microwave antigen retrieval with citrate buffer and...
immunohistochemistry (Vector Elite Peroxidase Kit; Vector Laboratories) or immunofluorescence. The following primary antibodies were used: CD34 (Novus), Cre (Novagen), GFAP (DAKO), and NeuN (Millipore). Secondary antibodies for immunohistochemistry were from Santa Cruz Biotechnology Inc., and those for immunofluorescence were from Molecular Probes. DAPI was purchased from Sigma-Aldrich. For Nile staining, sections were stained in 0.1% cresyl violet.

EPO ELISA. EPO protein in blood plasma was determined using the Quantikine Mouse EPO ELISA kit (R&D Systems) according to manufacturer’s protocol.

Western blot analysis. Snap-Frozen tissue was homogenized in buffer A (10 mM Tris, pH 8, 1 mM EDTA, pH 8, 150 mM NaCl, 0.5% NP 40, 1 mM PMSF) and with complete PI tablets; Roche) to yield cytoplasmic protein. Nuclear proteins were extracted in buffer B (20 mM Heps, pH 7.9, 400 mM NaCl, 1 mM EDTA, pH 8, 1 mM DTT, 1 mM PMSF). 30 µg of nuclear protein was separated on 4%–8% Tris-Acetate Gels (Invitrogen) followed by immunoblotting as described (48). Primary antibodies for HIF-1α and HIF-2α were from Novus Biologicals. Equal loading was documented by Coomassie staining.

fMRI. The mice were imaged in vivo under isoflurane anesthesia using a Bruker 7 Tesla small animal magnetic resonance imaging scanner. The images were acquired with a 1.5-cm custom-built surface MRI coil, which was manually tuned. T1 and T2 weighted images were acquired using a T1 parameters were as follows: TE/TR 35.2/16716 ms, 4 averages. T2 parameters were as follows: TE/TR 7.1/3358 ms, 6 averages. T2 weighted images were acquired using a 1.5-cm custom-built surface MRI coil, which was used for the analysis of differences in mean values between groups. Significance was defined as P < 0.05.

Acknowledgments
A. Weidemann was supported by a fellowship of the German Research Foundation (DFG WE4275/1-1). C. Stockmann was supported by a fellowship of the German Research Foundation (STO 787/1-1). We thank J. Choi and M. Salcedo for technical assistance. We thank D. Liao, B. Blouw, P. Blinder, B. Friedmann, C. Schachtrup, N. Zhang, C. Warnecke, M. Wiesen, and K.U. Eckardt for technical advice, helpful conversations, and discussions.

Received for publication March 30, 2009, and accepted in revised form August 5, 2009.

Address correspondence to: Randall S. Johnson, Division of Biology, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92039, USA. Phone: (858) 822-0509; Fax: (858) 822-5832; E-mail: rjsjohnson@ucsd.edu.


